iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
Ticker SymbolICAD
Company nameICAD Inc
IPO dateDec 13, 1984
CEOMs. Dana R. Brown
Number of employees66
Security typeOrdinary Share
Fiscal year-endDec 13
Address98 Spit Brook Rd Ste 100
CityNASHUA
Stock exchangeEuronext Paris
CountryUnited States of America
Postal code03062-5737
Phone16038825200
Websitehttps://www.icadmed.com/
Ticker SymbolICAD
IPO dateDec 13, 1984
CEOMs. Dana R. Brown
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data